

## Appendix A: Conflict of Interest Disclosure Form

### CADTH Expert Committee and Panel Members

I have read and understood the Conflict of Interest (COI) Guidelines and I agree to be bound by the obligations contained therein. I understand that it is my responsibility to report to CADTH any real, potential or perceived conflicts of interest as defined in the COI Guidelines, and to disclose the information requested in the COI Guidelines.

As a member of a CADTH Committee or Panel, I also understand that a summary of my expertise, experience, affiliations and conflict of interest declaration will be publicly available on the CADTH website and in all CADTH publications to which I have contributed in an advisory (i.e. have made recommendations) or authorship role.

I understand that the information disclosed will be retained on file by CADTH.

I have reviewed my investments, affairs, affiliations, activities and interests and have accurately completed the attached Schedules 1, 2 and 3.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation. Except as otherwise disclosed in the attached Schedules 1, 2 and 3, I declare that I have no conflict of interest to report, as defined in the COI Guidelines.

I undertake and promise to inform CADTH of any change in circumstances that may create a conflict of interest as soon as it is known to me.



June 21st 2018

Christian Kollmannsberger

Date

Print Name

Signature

pERC Committee

Name of Committee/Panel

## Conflict of Interest Disclosure Form – Schedule 1

(Reference: COI Guidelines Section 5.3)

Disclosures are required under Section 5.3 of the Conflict of Interest Guidelines for those activities or interests involving any Party during the past three years which benefited the Member or related person, particularly as the activities relate to the following areas (add pages as necessary):


Name of Party (see section 2.2 for definition)	Drug, technology or topic involved and year of funding
Pfizer	Sunitinib / Axitinib 2016-2018
BMS	Nivolumab 2017/2018
Sanofi	Cabazitaxel 2018
Novartis	Pazopanib 2016

**\*Other gifts/funding/honoraria: please provide details:**

I do not have declarations for Schedule 1.

June 21st 2018

Kollmannsberger



Date

Print Name

Signature

## Conflict of Interest Disclosure Form – Schedule 2

(Reference: COI Guidelines Section 5.4)

Disclosures are required under Section 5.4 of the Conflict of Interest Guidelines for those activities or interests involving any Party during the past three years which benefited the Member or their immediate family members, particularly as the activities relate to the following areas (add pages as necessary):

**For each Party and drug, technology or topic, identify the type of funding or benefit received and indicate the total value (dollar range).**

Name of Party (see section 2.2 for definition)	Drug, technology or topic involved and year of funding
Pfizer	Sunitinib/Axitinib 2016-2018
Ipsen	Cabozantinib 2017/2018
Eisai	Lenvatinib 2018
BMS	Nivolumab 2016-2018
Astellas	Enzalutamide 2017/2018

**\*\*Payments as advisor/consultant: please provide details:**

Participation in ad hoc advisory boards

I do not have declarations for Schedule 2.

June 21st 2018

Kollmannsberger



Date

Print Name

Signature

## Conflict of Interest Disclosure Form – Schedule 3

(Reference: COI Guidelines Section 5.5)

List those activities, affiliations or interests involving a Party in the past three years (not already listed in Schedules 1 and 2) that may affect or compromise, or appear to affect or compromise the Member’s objectivity, fairness or professional judgment (as outlined in Section 5.5.1). See list of examples in Section 5.5.2.

Name of Party (see section 2.2 for definition)	Nature or description of activities or interests (see Section 5.5.2)

List those activities, affiliations or interests involving a Party with whom the Member has a potential or pending future commitment (as outlined in Section 5.5.3). Provide details on the nature of the commitment.

Name of Party (see section 2.2 for definition)	Nature and timing of the future commitment

I do not have declarations for Schedule 3.

June 21st 2018

Kollmannsberger



Date

Print Name

Signature